199 related articles for article (PubMed ID: 9784014)
1. Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
Exp Toxicol Pathol; 1998 Sep; 50(4-6):397-401. PubMed ID: 9784014
[TBL] [Abstract][Full Text] [Related]
2. Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):258-65. PubMed ID: 9885410
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Shephard SE; Nestle FO; Panizzon R
Photodermatol Photoimmunol Photomed; 1999 Apr; 15(2):64-74. PubMed ID: 10321518
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal methoxsalen: new drug. Cutaneous T cell lymphoma: for rare patients, but better assessment needed.
Prescrire Int; 2009 Feb; 18(99):16. PubMed ID: 19388212
[No Abstract] [Full Text] [Related]
6. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
7. Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
Holien T; Gederaas OA; Darvekar SR; Christensen E; Peng Q
Lasers Surg Med; 2018 Jul; 50(5):469-475. PubMed ID: 29460964
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induction by extracorporeal photopheresis is enhanced by increasing the 8-methoxypsoralen concentration and by replacing plasma with saline.
Hähnel V; Brosig AM; Ehrenschwender M; Burkhardt R; Offner R; Ahrens N
Transfusion; 2021 Oct; 61(10):2991-2999. PubMed ID: 34427336
[TBL] [Abstract][Full Text] [Related]
9. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications.
Hackstein H; Misterek J; Nockher A; Reiter A; Bein G; Woessmann W
Transfusion; 2009 Nov; 49(11):2366-73. PubMed ID: 19903292
[TBL] [Abstract][Full Text] [Related]
10. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
11. Parenteral administration of 8-methoxypsoralen in photopheresis.
Knobler RM; Trautinger F; Graninger W; Macheiner W; Gruenwald C; Neumann R; Ramer W
J Am Acad Dermatol; 1993 Apr; 28(4):580-4. PubMed ID: 8463458
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis: clinical use so far.
Sanford KW; Balogun RA
J Clin Apher; 2012; 27(3):126-31. PubMed ID: 22467383
[TBL] [Abstract][Full Text] [Related]
14. The North American experience with photopheresis.
Zic JA; Miller JL; Stricklin GP; King LE
Ther Apher; 1999 Feb; 3(1):50-62. PubMed ID: 10079806
[TBL] [Abstract][Full Text] [Related]
15. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia E; Vonderheid EC; Geskin L
Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
[TBL] [Abstract][Full Text] [Related]
16. Modification of extracorporeal photopheresis technology with porphyrin precursors. Comparison between 8-methoxypsoralen and hexaminolevulinate in killing human T-cell lymphoma cell lines in vitro.
Cunderlíková B; Vasovič V; Randeberg LL; Christensen E; Warloe T; Nesland JM; Peng Q
Biochim Biophys Acta; 2014 Sep; 1840(9):2702-8. PubMed ID: 24915603
[TBL] [Abstract][Full Text] [Related]
17. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.
Heald PW; Perez MI; Christensen I; Dobbs N; McKiernan G; Edelson R
Yale J Biol Med; 1989; 62(6):629-38. PubMed ID: 2534648
[TBL] [Abstract][Full Text] [Related]
18. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
19. A standardized methodical approach to characterize the influence of key parameters on the in vitro efficacy of extracorporeal photopheresis.
Laulhé M; Lefebvre S; Le Broc-Ryckewaert D; Pierre M; Ferry A; Delorme B
PLoS One; 2019; 14(3):e0212835. PubMed ID: 30822323
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photopheresis: past, present, and future.
Knobler R; Barr ML; Couriel DR; Ferrara JL; French LE; Jaksch P; Reinisch W; Rook AH; Schwarz T; Greinix H
J Am Acad Dermatol; 2009 Oct; 61(4):652-65. PubMed ID: 19665258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
